According to the American Academy of Child and Adolescent Psychiatry (AACAP), attention-deficit/hyperactivity disorder (ADHD) affects 3% to 5%of school-age children, and it is estimated that 4% of adults in the U.S. have ADHD. Clinicians that treat those with this disorder can now refer to guidelines that include the only medication indicated specifically for the treatment of this condition in children, adolescents, and adults. AACAP recently issued updated guidelines for managing ADHD and recommended atomoxetine (Strattera, Eli Lilly) as a first-line therapeutic option.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.